GeneDx Holdings Corp (WGS) FinancialsWGSGeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Patients with third party insurance, accounting for 82.8% of total sales, equivalent to $94.73M. Other significant revenue streams include Institutional customers and Other. Understanding this composition is critical for investors evaluating how WGS navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, GeneDx Holdings Corp. maintains a gross margin of 68.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.25%, while the net margin is -15.50%. These profitability ratios, combined with a Return on Equity (ROE) of -40.80%, provide a clear picture of how effectively WGS converts its operational activities into shareholder value.

In the context of the broader market, WGS competes directly with industry leaders such as ACHC and NEO. With a market capitalization of $2.33B, it holds a significant position in the sector. When comparing efficiency, WGS's gross margin of 68.37% stands against ACHC's 100.00% and NEO's 45.56%. Such benchmarking helps identify whether GeneDx Holdings Corp. is trading at a premium or discount relative to its financial performance.

GeneDx reported a total revenue of $114.4 million in Q2 2026, achieving a gross margin of 70%, up from 69% in Q1. The company also returned to profitability earlier than expected, with adjusted net income of $0.4 million, a significant improvement from previous quarters.